Last reviewed · How we verify
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (XANAP)
This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.
Details
| Lead sponsor | Bayer |
|---|---|
| Status | COMPLETED |
| Enrolment | 2297 |
| Start date | Sun Jan 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Oct 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Atrial Fibrillation
Interventions
- Rivaroxaban (Xarelto, BAY59-7939)
Countries
Pakistan, Hong Kong, Malaysia, Taiwan, Indonesia, Vietnam, South Korea, Philippines, Thailand, Singapore, India